Regeneron Pharmaceuticals (REGN) Enterprise Value (2009 - 2026)

Regeneron Pharmaceuticals' Enterprise Value history runs 18 years deep, the most recent figure standing at -$8.8 billion for Q1 2026.

• In Q1 2026, Enterprise Value fell 4.84% year-over-year to -$8.8 billion; the TTM figure through Mar 2026 stood at -$8.8 billion (down 4.84% YoY), while the FY2025 annual figure was -$8.6 billion, up 4.52% from the prior year.
• Enterprise Value was -$8.8 billion for Q1 2026 at Regeneron Pharmaceuticals, down from -$8.6 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$7.0 billion in Q3 2022 to a low of -$10.8 billion in Q4 2023.
• Historically, Enterprise Value has averaged -$8.8 billion across 5 years, with a median of -$8.8 billion in 2026.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value plunged 101.23% in 2022, then advanced 23.85% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$7.7 billion in 2022, then sank by 40.07% to -$10.8 billion in 2023, then grew by 16.9% to -$9.0 billion in 2024, then climbed by 4.52% to -$8.6 billion in 2025, then dropped by 1.73% to -$8.8 billion in 2026.
• The last three Enterprise Value figures came in at -$8.8 billion (Q1 2026), -$8.6 billion (Q4 2025), and -$8.4 billion (Q3 2025), per Business Quant data.